Physician profile
Hunter Ries
NPI 1841933363
$271.69
in general payments reported to CMS, 2019-2025
10 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.24 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.94 | 2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $41.63 | 2025 | Rexulti |
| Novo Nordisk INC | $34.42 | 2022-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.92 | 2025 | Xifaxan |
| Avita Medical Americas, LLC | $27.18 | 2025 | Permeaderm, Recell, Cohealyx |
| Inspire Medical Systems, INC. | $24.00 | 2025 | Inspire |
| Pfizer INC. | $19.02 | 2025 | |
| Exact Sciences Corporation | $18.11 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.80 | 2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Ries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.